Activartis has received European orphan drug designation for a cancer immune therapy, AV0113, for use in the treatment of glioma. AV0113, which was developed against every type of cancer, is based on a procedure where the immune system ...
Tags: orphan drug, cancer immune therapy
The European Commission and the European Medicines Agency have issued orphan drug designation to PROLOR Biotech's hGH-CTP. The longer-acting version of human growth hormone, hGH-CTP, is being developed to treat growth hormone deficiency. ...
Tags: PROLOR Biotech, hGH-CTP, European Orphan Drug Designation
The European Commission (EC) has granted orphan drug designation to Sunesis Pharmaceuticals' Vosaroxin drug. Vosaroxin is a first-in-class anti-cancer quinolone derivative, (AQD), used for the treatment of acute myeloid leukemia (AML). ...
Tags: vosaroxin, AQD, AML, anti-cancer quinolone derivative